Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.
Conaghan PG, Mysler E, Tanaka Y, Da Silva-Tillmann B, Shaw T, Liu J, Ferguson R, Enejosa JV, Cohen S, Nash P, Rigby W, Burmester G.
Conaghan PG, et al.
Drug Saf. 2021 May;44(5):515-530. doi: 10.1007/s40264-020-01036-w. Epub 2021 Feb 2.
Drug Saf. 2021.
PMID: 33527177
Free PMC article.
Review.